Pfizer and Astellas Announce Co-promotion Agreement for Caduet Combination Tablets
TOKYO, August 26, 2009 – Pfizer Japan Inc. (“Pfizer”) and Astellas Pharma Inc. (“Astellas”) today announced that the companies have reached a co-promotion agreement for a combination drug of hypertension treatment and hypercholesterolemia treatment Caduet® Combination Tablets (generic name: amlodipine besylate and atorvastatin calcium) in Japan.
Pursuant to this agreement, Pfizer is responsible for
manufacturing and sales of Caduet Combination Tablets, and Pfizer
and Astellas will co-promote it. Sales will be booked at Pfizer,
and Astellas will receive fee in a way that the companies
agreed. The term of this agreement is until July 2016.
Caduet Combination Tablets is an oral combination drug of a
hypertension treatment Norvasc® Tablets (generic name:
amlodipine besylate) sold by Pfizer and a hypercholesterolemia
treatment Lipitor® Tablets (generic name: atorvastatin calcium)
co-promoted by Pfizer and Astellas. Caduet Combination Tablets is a
single tablet to combine the most prescribed drugs for hypertension
and hypercholesterolemia to help with both treatments, and it is
expected to improve medication adherence. Caduet Combination
Tablets is now approved in more than 70 countries/areas, and Pfizer
has obtained approval to manufacture and market Caduet Combination
Tablets in Japan on July 7, 2009.
Pfizer and Astellas have established great partnership through
co-promotion of Lipitor Tablets. The companies are committed to
work hard to maximize the product value of Caduet Combination
Tablets and expect to further contribute to hypertension and
hypercholesterolemia treatment.
Caduet Combination Tablets will be available after it is listed on
Japan's National Health Insurance drug price list.
Posted: August 2009
